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Abstract
Background: Intravenous methylprednisolone (IV-MP) is an established treatment for multiple
sclerosis (MS) relapses, accompanied by rapid, though transient reduction of gadolinium enhancing
(Gd+) lesions on brain MRI. Intermittent IV-MP, alone or with immunomodulators, has been
suggested but insufficiently studied as a strategy to prevent relapses.
Methods: In an open, single-cross-over study, nine patients with relapsing-remitting MS (RR-MS)
underwent cranial Gd-MRI once monthly for twelve months. From month six on, they received a
single i.v.-infusion of 500 mg methylprednisolone (and oral tapering for three days) after the MRI.
Primary outcome measure was the mean number of Gd+ lesions during treatment vs. baseline
periods; T2 lesion volume and monthly plasma concentrations of cortisol, ACTH and prolactin
were secondary outcome measures. Safety was assessed clinically, by routine laboratory and bone
mineral density measurements. Soluble immune parameters (sTNF-RI, sTNF-RII, IL1-ra and
sVCAM-1) and neuroendocrine tests (ACTH test, combined dexamethasone/CRH test) were
additionally analyzed.
Results: Comparing treatment to baseline periods, the number of Gd+ lesions/scan was reduced
in eight of the nine patients, by a median of 43.8% (p = 0.013, Wilcoxon). In comparison, a pooled
dataset of 83 untreated RR-MS patients from several studies, selected by the same clinical and MRI
criteria, showed a non-significant decrease by a median of 14% (p = 0.32). T2 lesion volume
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decreased by 21% during treatment (p = 0.001). Monthly plasma prolactin showed a parallel decline
(p = 0.027), with significant cross-correlation with the number of Gd+ lesions. Other hormones
and immune system variables were unchanged, as were ACTH test and dexamethasone-CRH test.
Treatment was well tolerated; routine laboratory and bone mineral density were unchanged.
Conclusion: Monthly IV-MP reduces inflammatory activity and T2 lesion volume in RR-MS.
Background
Intravenous methylprednisolone (IV-MP), 500–1000 mg
for 3–5 days, is an established treatment for acute relapses
of multiple sclerosis, speeding recovery [1,2]. It does not
prevent future relapses. However, a study in isolated optic
neuritis suggested that a single course of IV-MP may delay
the occurrence of another episode of inflammatory demy-
elination and thus conversion to definite MS according to
Poser's criteria [3,4]. Repeated administration of IV-MP in
regular intervals may extend these beneficial effects, but
this approach has not been fully evaluated and requires
further study [5]. In secondary progressive MS, IV-MP
every two months showed partial, dose-dependant benefit
in several secondary endpoints [6]. In relapsing-remitting
MS, a five-day course of IV-MP every four to six months
slowed progression of MRI measures of brain atrophy, as
compared to treatment for relapses only [7].
The mechanisms underlying the beneficial effects of corti-
costeroids in MS remain incompletely understood. Rapid
reduction of inflammatory blood-brain-barrier (BBB) dis-
ruption, as shown by disappearance of gadolinium (Gd)
enhancement after few days of treatment [8-10], is a
prominent effect. Corticosteroids are also potent immu-
nomodulatory drugs, inhibiting the expression of inflam-
matory mediators (including TNF and leukocyte-
endothelial cell adhesion molecules) and cellular immu-
nity (reviewed in [11]). Further, the endocrine and
immune systems closely interact (reviewed in [12]), with
ACTH, cortisol, prolactin (PRL) and growth hormone
(hGH) being most often implicated in the regulation of
the immune system. We [13,14] and others [15] have
described a disturbed regulation of the hypothalamo-
pituitary-adrenal (HPA) axis in MS, as well as hyperprol-
actinemia during acute attacks [16]. While causal relations
are at present difficult to establish, corticosteroids do
affect the secretion of several other hormones, and may
thus have indirect effects on the immune system.
It is unknown if these effects remain active with regular
administration. In order to study the effect of pulsed cor-
ticosteroids on several of these aspects, we administered a
single infusion of MP, once per month, to RR-MS patients.
Based on guidelines derived from natural history and
treatment trial data [17,18], we designed a single-cross-
over study with a six-month baseline and a six-month
treatment period, and determined the impact on
1. inflammatory disease activity as shown by BBB disrup-
tion (frequency of Gd-enhancing lesions on brain MRI),
2. total T2 lesion load,
3. plasma hormone concentrations and dynamic meas-
ures of neuroendocrine regulation, and
4. selected plasma markers of immune function.
Methods
Study design
Participation in this open-label, single-cross-over study
was offered to patients with clinically definite [19], relaps-
ing-remitting MS, followed in a natural history study with
monthly Gd-enhanced MRI. Patients could enter that
study no earlier than three months after the last relapse or
course of IV-MP. In each individual patient, scans were
performed at the same time of the day, and blood was
drawn from an antecubital vein before each scan. We first
selected those patients who had at least one Gd-enhanc-
ing lesion on the first three scans, and continued monthly
visits for another three months. Final inclusion in the
treatment trial required that the first six monthly scans
showed at least three Gd-enhancing lesions (i.e. a mean of
0.5 Gd+ lesions per scan). Further inclusion criteria were:
one or more relapses during the two years before the first
MRI scan, contraindication to immunosuppressive or
immunomodulatory therapy or decline of these therapies
by the patient, and no contraindications to glucocorticoid
treatment. Upon inclusion, monthly MRI and blood sam-
pling was continued until month 12. Treatment started
after the MRI at month 6 (see below).
The study was performed and funded by the participating
institutions, with no external funding. It was approved by
the ethics committee of the Bavarian State Board of Physi-
cians (Bayerische Landesärztekammer). Patients gave
written informed consent.
Patients
Twenty-five patients were screened by three monthly MRI
scans. Ten patients fulfilled the inclusion criteria, but we
excluded one patient with a very high baseline activity to
reduce the risk of regression to the mean. See table 1 for
clinical and demographic characteristics of the finally
included nine patients, and figure 1 for a study flow chart.BMC Neurology 2006, 6:19 http://www.biomedcentral.com/1471-2377/6/19
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None of the patients had ever been treated with immuno-
suppressive or immunomodulatory drugs; mean annual-
ized relapse rate during the entire disease duration was
0.68, and during the two years prior to study inclusion,
0.8.
Magnetic resonance imaging
Once every month, brain MRI was performed on the same
1.5T Signa Echospeed (GE Medical Systems), including
axial T1-weighted sequences (TR = 640 ms, TE = 14 ms, 4
mm thick, 1 mm gap) as well as a proton density and T2
weighted dual fast spin echo sequence (TR = 3600 ms, TE
= 13 and 91 ms, resp.) and a FLAIR sequence (TR = 10 s,
TE = 133 ms, TI = 2200 ms) inherently coregistered with
the T1 axial scans. Axial and coronal (3 mm thick, 1.5 mm
gap) T1-weighted sequences were acquired after i.v. injec-
tion of 0.1 mmol/kg gadolinium chelate (Omniscan(R)),
with the interval between injection and first axial scan
standardized at 6 minutes.
The number of Gd-enhancing lesions on brain MRI was
determined by a blinded radiologist (E.S.) on the scans
presented in random order, with the date of acquisition
masked. For each patient, the mean number of active
lesions per scan was calculated for baseline and treatment
period. To determine lesion volume and BFV, a neural
network based image analysis system was used as
described [20]. Briefly, data preprocessing included man-
ual delineation of the intracranial cavity contents, auto-
matic grey value correction (coil inhomogeneity and
interslice differences) and extraction of a small training
data subset by interactive contour tracing of regions repre-
senting the structure classes: normal appearing grey mat-
ter (GM), normal appearing white matter (WM), cerebro-
spinal fluid (CSF), and MS lesion. A hierarchical vector
quantization approach was then deployed to segment the
multi-dimensional image data into five classes: GM, WM,
CSF, lesions and other (comprising meninges, vessels).
Table 1: Demographic characteristics and primary outcome measure, the number of active lesions/scan (Mean [SEM])
Patient Age Sex EDSS Duration of 
disease
Mean number of active lesions 
per monthly scan
Change, 
mean lesion 
number
F/M years baseline period treatment 
period
%
All patients 32.7 [1.4] 8/1 1.5 [0.33] 6.3 [2.0] 3.55 [0.78] 2.15 [0.69] - 39.4 
p = 0.013*
01 25 F 0 1 1 0,5 - 50
02 32 F 0 2.5 1.83 0 - 100
03 31 F 2.0 5 7.67 5.83 - 34
04 34 F 1.5 4 2.33 2.83 + 21
05 34 F 1.0 0.3 6 3.67 - 38
06 36 M 2.5 11.3 4.5 0.67 - 85
07 40 F 2.5 15 1 0.17 - 83
08 33 F 2.5 15 4.83 4.17 - 14
09 30 F 1.5 3 2.67 1.5 - 38
Median change - 43.8 %
Mean change - 46.4 %
* p for testing baseline vs. treatment period (Wilcoxon Matched-Pairs Signed-Ranks test for related samples).
Study flow chart Figure 1
Study flow chartBMC Neurology 2006, 6:19 http://www.biomedcentral.com/1471-2377/6/19
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The BFV was determined as the ratio of pixels belonging
to either brain, i.e. GM, WM or MS lesions, to those
belonging to brain or CSF. CSF segmentation was based
on the image information obtained by all acquired MRI
sequences; MS-lesions were identified based on T2, PD,
and FLAIR data. The segmentation performance com-
pared favorably (higher retest stability) with the more
standard region growing segmentation algorithm for T2
lesion load (T2-LL) and angle image [21] for BFV [20]. T2-
LL and BFV were calculated for four time points (start and
end of baseline: months 1 and 6; and four weeks after the
first and the last MP infusion: months 7 and 12).
Treatment
From month six to eleven, patients received 500 mg MP
i.v. after each MRI scan, followed by an oral tapering dose
of 40, 20 and 10 mg MP for one day each to prevent any
potential temporary glucocorticoid deficiency.
Serum cytokine and hormone concentrations
Blood was collected, between 15:00 and 18:00 in the
afternoon and always before the MRI scan, into tubes con-
taining EDTA and trasylol, and plasma was stored at -80
degC until processing. sTNF-RI, sTNF-RII, IL-1ra and
sVCAM1 were quantified by commercial enzyme-linked
immunosorbent assay (ELISA) kits (s-TNF-RI and RII: Bio-
source Europe, Belgium; IL-1ra and VCAM-1: R&D Sys-
tems, Minneapolis, USA). Hormone concentrations were
measured using commercial radioimmuno (RIA) or
chemiluminescence assays (cortisol: RIA, DRG Instru-
ments, Germany; ACTH: RIA, and prolactin: Chemilumi-
nescence Immunoassay, both Nichols Institute
Diagnostics, San Juan Capistrano, CA, USA).
Dexamethasone-CRH test
The dexamethasone-CRH test (Dex-CRH test) was per-
formed, and values were derived, as described [13], once
before the start of treatment, and once between months
11 and 12.
Safety
In addition to a full physical and neurological examina-
tion including EDSS [22], blood chemistry (including cal-
cium, phosphate and vitamine D3), blood count, thyroid
function tests, urinanalysis and pyrrolidine cross-links in
urine were determined monthly. At baseline and after six
months of treatment, patients underwent the short ACTH
test (i.v. injection of 200 microgram tetracosactid [Syn-
acthen(R), Novartis] at 08:00, with determination of
plasma cortisol concentration before and 60 minutes after
injection) and CT densitometry of the lumbar spine. All
procedures were performed on an outpatient schedule.
Outcome measures
The mean number of Gd enhancing lesions per monthly
MRI scan was defined as the primary outcome measure. In
accordance with published guidelines and sample size
estimates [17,18], we planned to enroll ten patients. Sec-
ondary outcome variables were T2 lesion volume and
monthly plasma hormone concentrations. Serum
immune variables and results of neuroendocrine tests
were analysed in an exploratory fashion. Number of
relapses, EDSS, routine laboratory results and bone min-
eral density measures were safety variables, with study ter-
mination criteria predefined for the laboratory results.
Brain fractional volume (BFV) was determined to control
for global changes in brain volume, potentially resulting
in false results of T2 volume analyses; BFV was not an out-
come measure.
Data analysis
According to the data structure, the effect of treatment on
the number of active lesions, on hormone and cytokine
receptor concentrations was analyzed using the non-para-
metric Wilcoxon matched-pairs signed-ranks test and a
one-factorial univariate analyses of variance (ANOVA)
with repeated measures design. The continuous depend-
ent variables were transformed with the ln-transformation
[Y = ln (x+1)] before ANOVAs. Associations over time
between the number of active lesions to plasma hormone
concentrations and immunological parameters were ana-
lysed by cross-correlation analysis. Changes of T2-LL and
BFV, and all other laboratory results were analyzed by
MANOVA, and followed by univariate F-tests where
appropriate. As nominal level of significance, p = 0.05 was
accepted; it was corrected (according to Bonferroni correc-
tion procedure) for all post-hoc tests, in order to keep the
type I error less or equal to 0.05. Data are given as mean
+/- standard error of the mean (SEM).
Comparison group
The comparison group was extracted from the database
maintained at the Sylvia Lawry Center for Multiple Sclero-
sis Research. This database includes clinical and imaging
information on patients examined according to clinical
trial protocols at separate centers, including untreated
control groups from several large clinical trials and natural
history studies. Patients were selected based on the fol-
lowing criteria: A diagnosis of relapsing-remitting multi-
ple sclerosis, no current immunosuppressive or
immunomodulatory treatment, longitudinal Gd-MRI fol-
low-up over twelve months, presence of at least 1 new
Gd+ lesion during the first three months, and at least three
new Gd+ lesions during the first six months. This yielded
a group of 83 patients (55 females, mean age 34.4 +/- 0.8
years, mean duration of disease of 7.5 +/- 0.6 years). The
MRI protocols applied 0.1 mmol/kg of gadolinium
chelate. The mean interval between injection and post-BMC Neurology 2006, 6:19 http://www.biomedcentral.com/1471-2377/6/19
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contrast T1w imaging was 5.7 minutes; the delay was 5
minutes in 69 of the selected 83 patients, one minute in
one patient, and between 7.5 and 15 minutes in the
remaining patients. Monthly scans over the entire twelve-
month period were available for seven patients; among
the remaining patients, four to six scans over the first six-
month-period were available for 75 patients, and for both
six-month-periods for 57 patients. The mean number of
new Gd+ lesions was calculated for each individual
patient for the first and the second six-month-period and
expressed as mean number of Gd+ lesions per scan.
Results
During the treatment period, the mean number of active
lesions per scan was reduced in eight of the nine patients,
by 14 to 100% compared to the baseline period; the
number increased by 21% in one patient (table 1). The
median rate of reduction was 43.8%, and the mean rate of
reduction was 46.4%. The mean number of active lesions
averaged over the group was reduced from 3.55 per
month (baseline period) to 2.15 (treatment period, a
reduction by 39.4%), statistically significant by Wilcoxon
matched-pairs signed-ranks test (two-tailed p = 0.013).
Analysis of variance also revealed a significant effect of
time [Wilk's aver. multivariate test of significance; effect of
time: F(11,88) = 2.15, p = 0.025]. The anti-inflammatory
effect was apparent from the first scan on treatment (T1 in
figure 2). Tests with polynomial contrasts in ANOVA
revealed that the mean number of enhancing lesions can
be optimally fitted by a polynomial curve of third order
(effect of polynomial contrast of 3rd order: F(1,8) = 6.35,
sig of F = 0.036).
The comparison group had a mean of 2.95 Gd+ lesions
per scan during the first six months of observation. Over
the next six months, the frequency of new Gd+ lesions per
scan increased or decreased over a wide range in indidvid-
ual patients, yielding a median rate of change of -14.3%
(reduction), but a mean rate of change of +15.2%
(increase). When analyzing the group averages, the mean
number of new Gd+ lesions was reduced to 2.76 Gd+
lesions per scan (a reduction by 6.4%). These changes
were not significant (Wilcoxon, p = 0.32).
In the study population, there was also a significant time
effect on T2 lesion load (Wilk's multivariate test for effect
of time, p = 0.002; table 2). Over the five-month baseline
period, T2-LL increased by 13% (p < 0.001). The first MP
infusion led to a decrease in T2-LL (by 8%, p = 0.021 for
comparison of month 7 to month 6, the last baseline
scan), and repeated MP infusions further decreased T2-LL
until month 12 (p = 0.001 for comparison to month 7 or
to month 6), representing a total decrease of 21% during
the treatment period. The changes in BFV were not signif-
icant (p = 0.086; table 2).
IV-MP treatment exhibited a significant effect on mean
plasma prolactin concentrations during baseline vs. treat-
ment period, with lower concentrations during the treat-
ment period (Table 3; Wilks multivariate test in MANOVA
(F(1,8) = 7.32, p = 0.027). Cross correlation coefficients
revealed significant associations of lag -1 between plasma
prolactin concentrations and the number of active lesions
on MRI (Cross correlation coefficient: r = 0.728, p < 0.05).
This means that prolactin levels increase or decrease one
month before a corresponding change in the number of
active lesions is observed on MRI. Cortisol and ACTH did
not differ significantly between the baseline and treat-
ment period (table 3). Also, results of the dexamethasone-
CRH test were unchanged (table 3). There was no signifi-
cant effect of treatment on soluble TNF receptors, IL-1
Time course of the mean number of active lesions on  monthly Gd-enhanced brain MRI Figure 2
Time course of the mean number of active lesions on 
monthly Gd-enhanced brain MRI.
Table 2: T2 lesion load and brain fractional volume (Mean [SEM]).
Baseline period Treatment period
Month 1 Month 6 Change (mth 6 
vs. mth 1)
Month 7 Month 12 Change (mth 12 
vs. mth 7)
Change (mth 12 
vs. mth 6)
T2 lesion load 
(ml)
19.93 [4.8] 22.49 [4.64] + 13 %
p < 0.001
20.68 [4.23] 17.70 [4.17] - 14 %
p = 0.001
- 21%
p = 0.001
BFV (%) 86.4 [1.4] 86.1 [1.8] - 0.35 %
n.s.
85.9 [1.9] 83.9 [1.8] -2.33 %
n.s.
-2.56%
n.s.
Multivariate Wilk's test for T2 lesion load, p = 0.002, and for BFV, p = 0.086; p values given in the table are for univariate F tests.BMC Neurology 2006, 6:19 http://www.biomedcentral.com/1471-2377/6/19
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receptor antagonist or sVCAM1 (which increased slightly;
table 4).
Four relapses occurred during the baseline period (three
treated by three-day courses of IV-MP, and MRI performed
no earlier than ten days afterwards), and two mild
relapses during the treatment period (no additional ster-
oids administered). The relapses occurred in individual
patients, and all recovered to the previous level of impair-
ment. The mean EDSS score was almost unchanged
between baseline (1.45 +/- 0.30) and end of study (1.40
+/- 0.37). Apart from occasional sleep disturbance on the
day of infusion and mild flush-like sensations immedi-
ately following the infusion, treatment was well tolerated.
Results of routine laboratory investigations were
unchanged (not shown). All patients had an adequate rise
of plasma cortisol after i.v. tetracosactid ("short ACTH
test"), both at baseline and after six months of treatment
(table 3). Biochemical measures of bone metabolism (cal-
cium, phosphate, vitamin D3 in serum, and pyrrolidine
cross-links in urine, data not shown) as well as bone min-
eral density (CT densitometry of the lumbar spine: 140.34
+/- 15.79 before, 135.50 +/- 15.93 after treatment) were
not significantly changed.
Discussion
We show here that a single monthly infusion of 500 mg
methylprednisolone with a three-day oral taper can
reduce inflammatory disease activity in patients with
relapsing-remitting MS, without clinically relevant side
effects. Our data support and extend two previous studies
of pulsed steroid treatment in MS. In RR-MS patients, reg-
ular courses of IV-MP every four to six months, as com-
pared to treatment for clinical relapses only, delayed
accumulation of T1 hypointensities and brain atrophy [7].
Only a non-significant effect was seen on T2 lesion load,
and the frequency of gadolinium-enhancing lesions was
not assessed. In secondary analyses, disease progression
appeared to be delayed, while there was no effect on the
relapse rate. In secondary-progressive MS, repeated
courses of IV-MP every eight weeks delayed the time to
confirmed disease progression in a dose-dependant fash-
ion, while failing with respect to the proportion of
patients with disease progression (the primary outcome
measure) [6]. MRI was not performed in that trial. IV-MP
Table 4: Plasma cytokine receptor and VCAM-1 concentrations (Mean [SEM])
Baseline period Treatment period p*
sTNF-R I (ng/ml) 1.4 [0.05] 1.4 [0.09] n.s.
sTNF-R II (ng/ml) 3.3 [0.3] 3.4 [0.2] n.s.
IL-1 ra (pg/ml) 262.9 [43.2] 246.4 [37.8] n.s.
sVCAM-1 (ng/ml) 430.7 [28.9] 484.6 [52.6] n.s.
* p for comparisons of baseline vs. treatment periods, MANOVA
Table 3: Mean [SEM] of plasma hormone concentrations during the baseline and treatment period, and results of 
neuroendocrinological tests
Baseline period Treatment period p*
Plasma hormone 
concentrations (means of 
monthly tests)
Prolactin (ng/ml) 10.2 [0.8]* 8.7 [0.7]* 0.027
Cortisol (ng/ml) 114.4 [23.2] 122.4 [22.8] n.s.
ACTH (pg/ml) 17.4 [2.3] 19.9 [4.3] n.s.
DEX-CRH test
CORT max (ng/ml) 39.7 [8] 41.1 [14] n.s.
CORT AUC 147.5 [30] 152.8 [55] n.s.
ACTH max (pg/ml) 20.4 [5] 22.5 [11] n.s.
ACTH AUC 49.4 [7] 46.6 [11] n.s.
ACTH test
ACTH base (pg/ml) 24.40 [12.21] 28.69 [7.23] n.s.
CORT base (ng/ml) 175.1 [22.6] 169.9 [22.4] n.s.
CORT 60 min (ng/ml) 330.7 [59] 275.8 [26.5] n.s.
Delta Cort (ng/ml) 149.70 [35.67] 163.00 [32.40] n.s.
* p for comparisons of baseline vs. treatment periods, MANOVABMC Neurology 2006, 6:19 http://www.biomedcentral.com/1471-2377/6/19
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has previously been shown to rapidly, though transiently
reduce gadolinium enhancement in MS, when given for
several days for acute relapses [8-10,23]. Our study sug-
gests that in the absence of relapse, a single infusion has a
similar effect, and that the reduction of inflammatory
activity can be extended by repeat infusion.
With the single cross-over study protocol and the selection
of patients based on a minimum number of enhancing
lesions during the baseline period, a potential alternative
explanation for the reduction of enhancing lesions would
be "regression to the mean". The mean number of active
lesions during the baseline period is comparable to some
earlier studies using the same single cross-over design as
in this study, while it was lower in others [24-27]. Com-
parison to a pooled dataset showed that inflammatory
activity in our patients was high, but not exceptional (see
below). In addition, the sharpest decline in the slope of
the regression curve occurs between months 6 and 7, con-
comitant with the start of treatment. These factors make
pure "regression to the mean" highly unlikely.
In an effort to estimate the magnitude of regression to the
mean, we extracted a comparison group from a large data-
base of patients collected from various centers, who had
undergone regular contrast enhanced MRI over twelve
months as placebo patients of clinical trials. This compar-
ison group of 83 patients, selected by clinical and imaging
criteria equivalent to ours, had a mean frequency of Gd-
enhancing lesions which is higher than would be expected
for an unselected population of MS patients [28]. Of note,
this number tends to even underestimate the true fre-
quency of new lesions, since not all patients had strictly
monthly scans, and some new lesions with a short dura-
tion of enhancement may have been missed. By natural
history alone, the mean number of new enhancing lesions
in the comparison group changed over a wide range dur-
ing the following six months, resulting in a non-signifi-
cant reduction by 6.4% for the entire group. Thus, many
patients selected for a minimum frequency of active
lesions appear to continue on that above-average inflam-
matory activity, and at least over a subsequent six-month
period, "regression" to mean values as described in unse-
lected MS patient cohorts [28] applies to the selected
group only on a relatively limited scale. Importantly, even
if we conservatively assume a more pronounced effect of
regression to the mean in our patients, we can still con-
clude that monthly methylprednisolone contributed far
more to the reduction of inflammatory activity.
Corticosteroids and T2 lesion load
This study is the first to show a favorable effect of methyl-
prednisolone on T2 lesion volume. A potentially con-
founding effect of the dehydrating properties of high-dose
glucocorticoids, leading to pseudoatrophy [29,30], can be
largely excluded because (i) no accompanying brain vol-
ume decrease was seen and (ii) serial MP infusions led to
a cumulative decrease of T2 lesion volume. Previous stud-
ies over short [23,30,31] and longer periods [7] failed to
demonstrate changes in T2 lesion load. In short-term
studies of MP in acute exacerbations [23,30,31], an anti-
edematous effect can be expected to be particularly prom-
inent, while our patients received a single infusion in the
absence of acute relapse. Edema resolution thus appears
to contribute less to this change in T2 signal than other
histological changes (extent of gliosis, macrophage infil-
tration or remyelination).
The role of prolactin during corticosteroid treatment
The parallel time-course of prolactin and Gd-enhancing
lesions during both baseline and treatment with repeated
steroid infusions is intriguing with respect to a possible
role of prolactin in the autoimmune process. Elevated
plasma levels of prolactin have been described in MS
relapse, with return to normal concentrations upon recov-
ery [16]. In other studies, plasma levels were higher in MS
patients than in controls, albeit in the normal range [32],
or normal [33,34]. While the role of prolactin in human
immune function is a matter of debate (e.g., [35,36]),
experimental data appear to support an immunostimula-
tory effect of prolactin [37-39]. Elevated levels of endog-
enous or therapeutic glucocorticoids are associated with
clinically relevant immunosuppression [40] through sev-
eral mechanisms, and at the same time reduce expression
and secretion of prolactin [41,42]. A mere side-effect of
steroid administration is unlikely given the significant
cross-correlation with enhancing lesions during the base-
line period. It remains to be determined if lower prolactin
during treatment contributes to the reduction of inflam-
matory disease activity, or if blunted inflammation leads
to a reduced level of general stressors which non-specifi-
cally stimulate prolactin secretion.
Measures of immune function
The panel of immunological analyses performed in this
study was chosen based on specific hypotheses rather than
being designed as a comprehensive immunological
assessment of pulsed corticosteroid treatment. Focusing
on these selected parameters, we did not observe signifi-
cant changes associated with monthly IV-MP. However,
this does not argue against a lasting immunological effect
of pulsed steroids, which potentially could be measured
by additional markers.
Clinical prospects for pulsed glucocorticoids in MS
We are aware that the small number of patients studied
and lack of long-term data prohibit direct clinical conse-
quences from this study and we do not suggest pulsed cor-
ticosteroids as routine treatment. However, our study
demonstrates an anti-inflammatory effect with almost noBMC Neurology 2006, 6:19 http://www.biomedcentral.com/1471-2377/6/19
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relevant short-term side effects, and no indication for
adrenal insufficiency or osteopenia, in line with recently
published data [43]. Our results thus support further
research [17].
Conclusion
In relapsing-remitting multiple sclerosis, once-monthly IV
methylprednisolone reduces inflammatory activity as
measured by the best currently available surrogate meas-
ure (high-frequency contrast enhanced brain MRI). The
effect is sufficient to support further study of this
approach in certain groups of patients.
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